FDAnews
www.fdanews.com/articles/81483-abbott-labs-shares-seen-as-overvalued

ABBOTT LABS SHARES SEEN AS OVERVALUED

October 7, 2005

UBS Investment Research initiated coverage of Abbott Laboratories with a "reduce" rating and $37 target price.

Forbes (http://www.forbes.com/markets/2005/10/06/abbott-labs-earnings-pharmaceuticals-1006markets10.html?partner=rss)